GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 7,930,000 shares, a growth of 6.6% from the November 30th total of 7,440,000 shares. Based on an average daily volume of 1,350,000 shares, the short-interest ratio is currently 5.9 days. Approximately 9.1% of the company’s shares are short sold.

GoodRx Stock Up 3.1 %

Shares of GoodRx stock opened at $4.65 on Thursday. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company has a market capitalization of $1.77 billion, a P/E ratio of -155.00, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29. The business has a 50-day moving average of $5.01 and a two-hundred day moving average of $6.75.

Institutional Trading of GoodRx

A number of large investors have recently bought and sold shares of the business. American Century Companies Inc. acquired a new position in shares of GoodRx in the second quarter valued at approximately $18,183,000. Point72 Asset Management L.P. acquired a new position in GoodRx in the 3rd quarter worth $11,295,000. Rubric Capital Management LP boosted its stake in GoodRx by 76.5% in the 2nd quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after purchasing an additional 1,619,748 shares during the period. Millennium Management LLC raised its stake in shares of GoodRx by 36.5% in the 2nd quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after purchasing an additional 1,102,758 shares during the period. Finally, Franklin Resources Inc. bought a new stake in shares of GoodRx in the third quarter valued at about $5,675,000. 63.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GDRX shares. Mizuho initiated coverage on GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective on the stock. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Barclays cut their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Finally, Citigroup dropped their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.37.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.